Senzime AB (SEZI) AI Stock Analysis

• Market Cap: kr806.51M
• Dividend Yield: N/A
• Average Volume (3M): 534.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: 62.24%
• EPS Growth: 21.16%
• Country: SE
• Employees: 54
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.16
• Shares Outstanding: 157,215,040
• 10 Day Avg. Volume: 328,516
• 30 Day Avg. Volume: 534,125
• PEG Ratio: 0.17
• Price to Book (P/B): 1.95
• Price to Sales (P/S): 11.50
• P/FCF Ratio: -5.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: kr4.50 ▼(-12.28% Downside)

Senzime AB's overall stock score is primarily impacted by its financial performance and valuation challenges. Despite revenue growth, the company faces significant profitability and cash flow issues. Technical indicators also suggest bearish momentum, further weighing on the stock's attractiveness.

Positive Factors

Revenue Growth

Senzime's consistent revenue growth indicates a strengthening market presence and increasing adoption of its medical devices, which supports long-term business expansion.

Low Debt-to-Equity Ratio

A low debt-to-equity ratio suggests conservative financial management, providing Senzime with greater flexibility to invest in growth opportunities without the burden of high-interest obligations.

Improving Gross Profit Margin

An improving gross profit margin reflects operational efficiencies and better cost management, which can enhance profitability as the company scales.

Negative Factors

Negative Profit Margins

Persistent negative profit margins highlight challenges in achieving cost-effective operations, which could hinder long-term financial sustainability and shareholder returns.

Negative Cash Flow

Negative cash flows indicate that the company is not generating sufficient cash from its operations, which may limit its ability to invest in growth and meet financial obligations.

Negative Return on Equity

A negative return on equity suggests inefficiencies in using shareholder funds to generate earnings, which could impact investor confidence and future capital raising efforts.

Senzime AB Business Overview & Revenue Model

Company Description

Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.

How the Company Makes Money

Senzime AB generates revenue primarily through the sale of its medical devices and related consumables, including the TetraGraph system and its associated monitoring accessories. The company operates a business-to-business (B2B) model, supplying hospitals and healthcare facilities with its monitoring solutions. Key revenue streams include product sales, recurring sales of consumables, and potential licensing agreements for its technology. The company's financial performance may also benefit from strategic partnerships with healthcare providers and distributors, as well as participation in clinical studies that validate its products, thereby fostering further adoption in the market.

Senzime AB Financial Statement Overview

Summary

Senzime AB shows revenue growth but struggles with profitability and cash flow. The balance sheet is stable with low leverage, yet negative returns and cash flows indicate a need for strategic improvements.

Income Statement

Senzime AB has shown a positive revenue growth rate of 15.43% in the TTM, indicating potential market expansion. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has improved over time, but the company remains unprofitable with significant net losses.

Balance Sheet

The company maintains a low debt-to-equity ratio, suggesting conservative leverage and financial stability. However, the return on equity is negative, reflecting ongoing losses and inefficiencies in generating shareholder value. The equity ratio indicates a strong equity base relative to total assets.

Cash Flow

Senzime AB's cash flow situation is challenging, with negative operating and free cash flows. The free cash flow to net income ratio is above 1, indicating that cash flows are less negative than net income. However, the negative free cash flow growth rate and operating cash flow coverage ratio highlight ongoing cash flow difficulties.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	89.71M	58.48M	35.75M	14.03M	10.98M	9.34M
Gross Profit	36.52M	20.12M	8.34M	-4.39M	-4.92M	-7.90M
EBITDA	-76.66M	-95.53M	-118.82M	-120.05M	-73.20M	-36.96M
Net Income	-120.62M	-118.73M	-134.15M	-132.70M	-82.14M	-47.45M
Balance Sheet
Total Assets	411.39M	424.53M	433.54M	322.68M	174.62M	258.89M
Cash, Cash Equivalents and Short-Term Investments	106.63M	100.94M	151.01M	26.04M	74.87M	160.31M
Total Debt	14.47M	22.67M	11.47M	13.04M	1.63M	2.40M
Total Liabilities	63.13M	78.67M	58.06M	60.78M	24.04M	27.55M
Stockholders Equity	348.26M	345.86M	375.48M	261.90M	150.58M	231.35M
Cash Flow
Free Cash Flow	-121.59M	-126.28M	-121.73M	-141.89M	-84.30M	-38.66M
Operating Cash Flow	-103.01M	-105.94M	-113.91M	-136.78M	-81.33M	-38.34M
Investing Cash Flow	-21.01M	-20.34M	-7.82M	-4.98M	-2.97M	-327.00K
Financing Cash Flow	180.59M	75.86M	246.51M	92.36M	-945.00K	167.69M

Senzime AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEZI, the sentiment is Negative. The current price of 5.13 is below the 20-day moving average (MA) of 5.26, below the 50-day MA of 5.31, and below the 200-day MA of 5.55, indicating a bearish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 44.85 is Neutral, neither overbought nor oversold. The STOCH value of 38.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SEZI.

Senzime AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	66 Neutral	kr1.09B	46.67	6.93%	―	-5.80%	-65.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSSD	50 Neutral	kr1.16B	-25.50	―	―	38.43%	57.76%
INTEG.B	48 Neutral	kr275.75M	-7.39	-18.55%	―	0.62%	-82.70%
SEDANA	48 Neutral	kr983.44M	-24.19	-4.42%	―	13.48%	28.98%
BACTI.B	46 Neutral	kr613.27M	-28.83	-6.81%	―	-8.10%	62.08%
SEZI	43 Neutral	kr806.51M	-5.92	-36.55%	―	62.24%	21.16%

Senzime AB Corporate Events

Senzime’s next-generation TetraGraph cleared for sale in Japan

Senzime is a Swedish medical device firm known for its TetraGraph neuromuscular monitoring system, which is used to guide dosing of paralytic drugs and improve perioperative patient safety in operating rooms worldwide.
Senzime’s next-generation TetraGraph system has received regulatory clearance for sale in Japan from the PMDA, and the company has already received a first order for 80 monitors for delivery in the fourth quarter of 2025. The approval enables further commercialization in one of the world’s largest healthcare markets through Senzime’s long-standing partnership with Fukuda Denshi, which already markets integrated modules based on TetraGraph technology. With hundreds of Japanese hospitals using TetraGraph since 2019, a domestic market of roughly 15,000 operating rooms and nearly 3 million major surgeries annually, and updated clinical guidelines that reinforce quantitative neuromuscular monitoring, the clearance strengthens Senzime’s market positioning and commercial opportunity in Japan and may increase product uptake and upgrade activity among hospitals.

The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK4.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.

Senzime Launches EMGINE Sirius Software for Enhanced Neuromuscular Monitoring

Senzime AB has launched the EMGINE Sirius software suite, an innovative enhancement to its TetraGraph® system, which will be presented at the PostGraduate Assembly in Anesthesiology in New York. This new release, developed from extensive patient data and clinical collaborations, includes features like the TetraGraph Intubation Readiness Indicator and personalized neuromuscular monitoring, promising improved safety and efficiency in surgical procedures. The TetraGraph system, already widely used in various hospitals, is further validated by a Mayo Clinic study showing its superiority in detecting optimal intubation conditions, reinforcing Senzime’s position as a leader in neuromuscular monitoring technology.

The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK4.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.

Senzime Secures Landmark TetraGraph Order from UK NHS

Senzime AB has secured a significant order from a leading NHS hospital trust in the UK for 70 TetraGraph systems, marking its largest European order to date. This strategic win aligns with UK guidelines mandating quantitative monitoring in operating theaters, positioning Senzime for broader expansion and reinforcing its commitment to enhancing patient safety through advanced neuromuscular monitoring technology.

The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK4.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.

Senzime AB to Present at Key Investor Conferences

Senzime AB announced that its CEO, Philip Siberg, will present at the Redeye Medtech & Diagnostics Theme Event and the Biostock Summit. These presentations are part of Senzime’s ongoing efforts to engage with investors and highlight its leadership in personalized anesthesia solutions. The participation in these conferences underscores Senzime’s commitment to advancing its market presence and providing stakeholders with insights into its innovative medical technologies.

The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.00 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.

Senzime Establishes Nomination Committee for 2026 AGM

Senzime AB has formed a Nomination Committee for its 2026 Annual General Meeting, comprising representatives from major shareholders, including the Crafoord family and Segulah AB. This committee, which represents about 34% of the company’s voting rights, is tasked with preparing proposals for key positions and remuneration ahead of the 2027 AGM, reflecting Senzime’s commitment to structured governance and stakeholder engagement.

The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.00 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.

Senzime Unveils EMGINE Software to Enhance Neuromuscular Monitoring

Senzime AB has launched EMGINE, a next-generation software suite for its TetraGraph® platform, aimed at advancing neuromuscular monitoring. This new technology, which will be showcased at the ANESTHESIOLOGY 2025 conference, is built on extensive real-world data and offers enhanced patient safety and compliance with international guidelines. The EMGINE software, featuring advanced algorithms and noise-reduction technology, is expected to strengthen Senzime’s position in the medical device industry by providing hospitals with state-of-the-art monitoring capabilities.

The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.00 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.